-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Viridian Therapeutics, Lowers Price Target to $31

Benzinga·04/07/2026 18:12:09
Listen to the news
Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $36 to $31.